Next-Generation Selective Oncology Therapeutics
| Program | Indication | Discovery | Pre-clinical | IND-Enabling |
|---|
FIG 1: Molecular differences between Tumor / NAT / Healthy tissue
FIG 2: Ixgene Proprietary Target Selection Pipeline
Address: 63 Great Rd, Suite 107, Maynard, MA 01754, USA
Email: info@ixgene.com | Phone: +1 (774) 288-9100
Email: research@ixgene.com | Phone: +86 15061776107